AMGN

#80
Amgen Inc. - Common Stock
336.7 0 USD
+0.07%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
335.47
337.47
Годовой диапазон
267.83
391.29
Дневное изменение
+0.07%
Месячное изменение
-1.19%
6-месячное изменение
-1.90%
Годовое изменение
+18.83%
Предыдущее закрытие
336.4 8
Open
335.4 7
Low
335.4 7
High
337.4 7
Volume
3 578
Открыть полный график Full chart

Financials

Обзор Отчетность Статистика Дивиденды
Квартал Год
  • Market Capitalization 181.72 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry Производители лекарств — общие
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
24.49
Коэффициент цена/денежный поток
5.13
Дивиденды на акцию
2.52
Дивидендная доходность, %
2.79

Amgen Inc. - Common Stock

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

Новости